Cat:GMP-V-2019nCoV-SnAb008
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Description
Cat No.
GMP-V-2019nCoV-SnAb008
Products Name
Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)
Expression platform
Mammalian (human cell)
Isotypes
human IgG1
Bioactivity validation
Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity.
COVID-19 related neutralizing potency is validated by
1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell.
2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
Source
Mammalian (human cell)
Products description
Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1):GMP-V-2019nCoV-SnAb001,
is a potency validated COVID-19 SARS-CoV-2 neutralizing antibody.This This antibodies can either act as positive control in COVID-19 related vaccines and neutralizing antibodies discovery and development,
or act as a benchmark in SARS-CoV-2 neutralization potency assay.
GeneMedi’s validated COVID-19 neutralizing antibodies group including:GMP-V-2019nCoV-SnAb001(human IgG1),GMP-V-2019nCoV-SnAb002(human IgM),GMP-V-2019nCoV-SnAb003(human IGA),GMP-V-2019nCoV-SnAb004(mouse IgG1),and GMP-V-2019nCoV-SnAb005(Cynomolgus (Non human primate, NHP) IgG1).
Purity
Purity: ≥95% （SDS-PAGE）
Application
positive control in COVID-19 related vaccines and neutralizing antibodies discovery,
also act as a benchmark in SARS-CoV-2 neutralization potency assay.
Predicted Molecular Mass
positive control in COVID-19 related vaccines and neutralizing antibodies discovery,
also act as a benchmark in SARS-CoV-2 neutralization potency assay.
Formulation
Lyophilized from sterile PBS, PH 7.4
Storage
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
